Zacks: Analysts Expect Intellia Therapeutics Inc (NTLA) Will Post Earnings of -$0.46 Per Share

Wall Street brokerages expect Intellia Therapeutics Inc (NASDAQ:NTLA) to post earnings of ($0.46) per share for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Intellia Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.63). Intellia Therapeutics posted earnings per share of ($0.44) in the same quarter last year, which would suggest a negative year-over-year growth rate of 4.5%. The company is expected to report its next earnings results on Tuesday, October 30th.

On average, analysts expect that Intellia Therapeutics will report full-year earnings of ($1.97) per share for the current fiscal year, with EPS estimates ranging from ($2.25) to ($1.56). For the next year, analysts forecast that the business will post earnings of ($2.52) per share, with EPS estimates ranging from ($3.15) to ($1.94). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Wednesday, August 1st. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.03. Intellia Therapeutics had a negative return on equity of 31.54% and a negative net margin of 284.56%. The business had revenue of $7.68 million for the quarter, compared to analyst estimates of $6.39 million. During the same period last year, the company earned ($0.45) EPS. The firm’s revenue was up 30.2% on a year-over-year basis.

Several research analysts have recently issued reports on NTLA shares. ValuEngine upgraded Intellia Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. BidaskClub lowered Intellia Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 26th. Wedbush reiterated an “outperform” rating and set a $36.00 target price on shares of Intellia Therapeutics in a report on Friday, May 18th. Zacks Investment Research lowered Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 7th. Finally, TheStreet lowered Intellia Therapeutics from a “c-” rating to a “d” rating in a report on Monday, May 7th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Intellia Therapeutics has a consensus rating of “Buy” and a consensus price target of $34.14.

Shares of Intellia Therapeutics traded up $0.18, hitting $27.67, during midday trading on Friday, Marketbeat.com reports. The company had a trading volume of 404,637 shares, compared to its average volume of 665,178. Intellia Therapeutics has a 12 month low of $15.06 and a 12 month high of $35.99. The firm has a market capitalization of $1.19 billion, a P/E ratio of -14.72 and a beta of 2.93.

In other Intellia Therapeutics news, Director Jean Francois Formela sold 6,686 shares of Intellia Therapeutics stock in a transaction dated Tuesday, June 19th. The stock was sold at an average price of $27.96, for a total value of $186,940.56. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider John M. Leonard sold 8,400 shares of Intellia Therapeutics stock in a transaction dated Monday, May 14th. The shares were sold at an average price of $24.00, for a total value of $201,600.00. The disclosure for this sale can be found here. Insiders sold a total of 28,458 shares of company stock worth $764,361 in the last three months. Company insiders own 12.80% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. TIAA CREF Investment Management LLC increased its position in shares of Intellia Therapeutics by 5.4% in the fourth quarter. TIAA CREF Investment Management LLC now owns 40,415 shares of the company’s stock valued at $777,000 after acquiring an additional 2,076 shares during the last quarter. Legal & General Group Plc increased its position in shares of Intellia Therapeutics by 75.4% in the second quarter. Legal & General Group Plc now owns 5,427 shares of the company’s stock valued at $149,000 after acquiring an additional 2,333 shares during the last quarter. D.A. Davidson & CO. increased its position in shares of Intellia Therapeutics by 14.2% in the first quarter. D.A. Davidson & CO. now owns 19,219 shares of the company’s stock valued at $405,000 after acquiring an additional 2,395 shares during the last quarter. Great West Life Assurance Co. Can increased its position in shares of Intellia Therapeutics by 2.5% in the second quarter. Great West Life Assurance Co. Can now owns 97,031 shares of the company’s stock valued at $2,652,000 after acquiring an additional 2,395 shares during the last quarter. Finally, TRUE Private Wealth Advisors increased its position in shares of Intellia Therapeutics by 23.5% in the second quarter. TRUE Private Wealth Advisors now owns 13,296 shares of the company’s stock valued at $363,000 after acquiring an additional 2,533 shares during the last quarter. 59.81% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Further Reading: Average Daily Trade Volume – What You Need to Know

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply